Find a Clinical Trial

Filter

Showing 1 - 10 out of 18

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

Ischemic stroke, Transient ischemic attack

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Gemini 1

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Hercules

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

Multiple sclerosis

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PERSEUS

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

AbbVie ELASCI

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury

Spine injuries and disorders

All genders

18-70

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

AbbVie EAISE

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Stroke

All genders

30-80

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PFO-PAS

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Stroke

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ASPIRE

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Intracerebral hemorrhage

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ARCADIA

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Stroke

All genders

45+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

C2D2AI Participant Recruitment Feasibility Study

Cerebrovascular disease

All genders

50+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

C2D2AI Participant Recruitment Feasibility Study